Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Shares Issued (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Shares Issued for 6 consecutive years, with $800000.0 as the latest value for Q4 2025.

  • Quarterly Shares Issued rose 101.74% to $800000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.4 million through Dec 2025, up 111.06% year-over-year, with the annual reading at $15.7 million for FY2025, 5.53% up from the prior year.
  • Shares Issued for Q4 2025 was $800000.0 at Kymera Therapeutics, down from $2.2 million in the prior quarter.
  • The five-year high for Shares Issued was $48.7 million in Q1 2024, with the low at -$46.1 million in Q4 2024.
  • Average Shares Issued over 5 years is $3.7 million, with a median of $1.5 million recorded in 2021.
  • The sharpest move saw Shares Issued plummeted 21291.67% in 2021, then skyrocketed 4368.29% in 2023.
  • Over 5 years, Shares Issued stood at -$5.1 million in 2021, then skyrocketed by 98.39% to -$82000.0 in 2022, then surged by 4368.29% to $3.5 million in 2023, then crashed by 1416.09% to -$46.1 million in 2024, then soared by 101.74% to $800000.0 in 2025.
  • According to Business Quant data, Shares Issued over the past three periods came in at $800000.0, $2.2 million, and $13.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.